Swiss Biotechnology startup LimmaTech Biologics raises a €35M Series A round to combat emerging antimicrobial resistance

LimmaTech Biologics AG is a clinical stage biopharmaceutical company. It is advancing its proprietary vaccine pipeline to halt the increasing threat of global infections due to emerging antibiotic resistance (AMR) and sexually transmitted diseases. Here are details of LimmaTech Biologics‘ latest funding round :

🚀 Launch


🏭 Industry



Franz-Werner Haas (CEO), Patricia Martin (Managing Partner & Vice President Clinical and Regulatory Affairs), Michael Kowarik (Co-founder &CSO), Paul Wolfrom (Co-founder & CFO)

💸 Funding & Investors

INVESTMENT (October 2023)€35 million (Series A)
INVESTORS (October 2023)co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.

🎯 Funding purpose

Advance its technology platform and speed up the development of preclinical and clinical vaccine candidates targeting bacterial infections like shigellosis and gonorrhoea.

🌐 Country HQ

Switzerland (Zurich)

Leave a Reply

Your email address will not be published.